KRRO - NASDAQ
Korro Bio, Inc.
$11.08
+2.1%Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
At a Glance
Live SnapshotKorro Bio, Inc. Management Team
Dr. Ram Aiyar MBA, Ph.D.
Chief Executive Officer, President & Director
Compensation
$939,075
Mr. Vineet Agarwal M.B.A.
Chief Financial Officer
Compensation
$811,770
Dr. Kemi Olugemo M.D.
Chief Medical Officer
Compensation
$649,724
Mr. Todd Chappell M.B.A.
Chief Operating Officer
Dr. Loic Vincent Ph.D.
Chief Scientific Officer
Dr. Joshua Rosenthal Ph.D.
Co-Founder & Advisor
Mr. Andrew Fraley Ph.D.
Co-Founder & Advisor
Ms. Stephanie Engels
Senior Vice President and Head of People & Culture
Mr. Oliver Dolan
Senior Vice President of Finance & Principal Accounting Officer
Mr. Jeffrey M. Cerio J.D., Pharm.D.
Senior Vice President, General Counsel & Corporate Secretary
Compensation
$615,025
Korro Bio, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.84M and sold $231K worth of KRRO shares, resulting in $2.61M of net buying activity.
3 Months
207.6K
2.31M
17.6K
230.72K
+2.1M
+$2.08M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
36.1K
536.21K
0
0.00
+536K
+$536K
Top Buyers
Yang Rick
10 Percent Owner
$2.30M
Behbahani Ali
Director, 10 Percent Owner:
$89K
Meyers Rachel
Director
$89K
Bermingham Nessan
Director
$89K
Knobil Katharine
Director
$89K
Top Sellers
Aiyar Ram
Director, Officer: President And Ceo
$197K
Formela Jean Francois
Director
$34K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $2.61M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
KRRO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 21, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 17, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 11, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.